Table 1 Demographics, clinical features, PEG-J procedures and related complications

 Male

60%

 Age at disease onset (y)

53.9

(35-62)

± 6.8

 Age at PEG-J placement

69.4

(51-80)

± 6.4

 Age at LFV (y)

724

(61-82)

± 5.6

 Disease duration (y)

17.2

(10-33)

± 5.7

 Disease duration at PEG-J placement (y)

14.9

(6-28)

± 6.3

 Follow-up duration (mo)

61.3

(3-119)

± 32.6

 Active follow-up

23

 Patients acquired from other sites

3

 Deceased

6

 Discontinued

1

Patients with 23 (11-38) ± 8.2 months of follow-up (n=20)

baseline

LFV

 MDS-UPDRS pt. III score

31.6

(4-50)

± 14

33.5

(8-66)

± 15.2

 mH&Y stage

3

(2.5-4)

± 0.5

3

(2.5-4)

± 0.6

 Weight (kg)

57.5

(38-76)

± 10.8

57

(36-75)

± 11.3

 Morning dose (ml)

7.8

(3.6-12.5)

± 2.7

8.1

(3.6-12.6)

± 1.8

 Continuous infusion (ml/h)

3.1

(2-4.3)

± 0.7

3.3

(2-4.6)

± 0.8

 Extra dose (ml)

2.2

(1.3-3.5)

± 0.6

2.2

(0.5-3.5)

± 0.8

 Average extra doses per day

1.2

(0-3)

± 1.0

1.2

(0-5)

± 1.1

 Daily DLI dose (mg)

1072

(710-1486)

± 236.4

1152

(708-1698)

± 262

PEG-J procedures (n=156)

 First implants

30

 Scheduled replacements

53

 Not scheduled (unexpected) replacements

73

Complications related PEG-J replacements

Events

Patients

Device-related

 Accidental removal

1

1

 Device coloring

8

4

 Tube breaking/puncture

16

6

 Ext./int. bumper dislocation

21

9

 Candida colonization

1

1

 Tube dislocation

35

12

Patient-related

 Abdominal discomfort

9

5

 Granulation tissue

4

4

 Buried bumper syndrome

1

1

 Peristomal inflammation

4

4

Total

100

Stoma complications^a

 Candida infection

1

1

 Granuloma

9

3

 Erythema

44

13

 Serous secretions

20

3

 Sero-ematic secretions

2

1

 Purulent secretions

3

1

 Edema

6

2

Total

85